Pancreatic ductal adenocarcinoma concomitant with pancreatic metastases of clear-cell renal cell carcinoma: a case report

Table 1 Overview of the clinical course in the present case

Time point	Event
T = 0	ERCP with stenting of distal bile duct and EUS-FNA cytology of the pancreatic body due to painless jaundice (ex domo)
T = 5 days	Diagnosis of G2 PDAC of the pancreatic body in EUS-FNA cytology material (ex domo)
T = 5 weeks	Begin of FOLFIRINOX chemotherapy with neoadjuvant intent due to borderline resectability of PDAC and patient’s good general condition
T = 7 weeks	NSTEMI with subsequent coronary artery stenting and stop of FOLFIRINOX therapy
T = 8 weeks	Interdisciplinary decision for surgical therapy
T = 10 weeks	Total pancreatectomy with splenectomy and segmental portal/superior mesenteric vein resection and reconstruction, hemigastrectomy and cholecystectomy
T = 12 weeks	Worsening postoperative condition, including ischemic perforation of the stomach, colon ischemia, refractory shock, and multiple organ failure, leading to the patient’s death

ERCP endoscopic retrograde cholangiopancreatography, EUS-FNA endoscopic ultrasound-guided fine-needle aspiration, FOLFIRINOX folinic acid, fluorouracil, irinotecan, oxaliplatin, NSTEMI non-ST-segment elevating myocardial infarction, PDAC pancreatic ductal adenocarcinoma

ISSN: 1752-1947